Assessment of the Evolution of Cancer Treatment Therapies

Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present.

[1]  K. D. Hardman,et al.  Single-chain antigen-binding proteins. , 1988, Science.

[2]  V. Devita,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1970, Annals of internal medicine.

[3]  H. Golomb,et al.  COMBINED THERAPY FOR SMALL-CELL CARCINOMA OF THE BRONCHUS , 1976, The Lancet.

[4]  E. Genden,et al.  Evolution of the management of laryngeal cancer. , 2007, Oral oncology.

[5]  M. Amiji,et al.  Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors , 2007, Cancer Gene Therapy.

[6]  F. Hall,et al.  Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. , 2010, International journal of oncology.

[7]  Daniela S Krause,et al.  Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.

[8]  Tsuneo Imai,et al.  Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes , 2009, Breast Cancer Research and Treatment.

[9]  Indrajit Roy,et al.  Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. , 2003, Journal of the American Chemical Society.

[10]  M. Barnes,et al.  Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer , 2010, Gene Therapy.

[11]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[12]  A. Gilman.  Therapeutic applications of chemical warfare agents. , 1946, Federation proceedings.

[13]  M. Wintrobe.  Nitrogen mustard therapy. , 1948, The American journal of medicine.

[14]  Kevin C Weng,et al.  Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. , 2008, Nano letters.

[15]  Minming Zhang,et al.  Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells , 2010, International journal of nanomedicine.

[16]  I. S. Johnson,et al.  THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. , 1963, Cancer research.

[17]  N. Ishiguro,et al.  Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model. , 2010, The Journal of bone and joint surgery. British volume.

[18]  Philip S Low,et al.  Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.

[19]  M. Brock,et al.  Lung cancer: New surgical approaches , 2007, Respirology.

[20]  E. Hall,et al.  Intensity-modulated radiation therapy, protons, and the risk of second cancers. , 2006, International journal of radiation oncology, biology, physics.

[21]  L. Goodman,et al.  NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .

[22]  Nuria Sanvicens,et al.  Multifunctional nanoparticles--properties and prospects for their use in human medicine. , 2008, Trends in biotechnology.

[23]  Pharmaceutical Press,et al.  Handbook of Pharmaceutical Excipients , 2012 .

[24]  Peter Wust,et al.  Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme , 2006, Journal of Neuro-Oncology.

[25]  Roland Felix,et al.  The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma , 2006, Journal of Neuro-Oncology.

[26]  P. Nelson,et al.  The state of antibody therapy. , 2010, Human immunology.

[27]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[28]  S. Singletary.  Minimally invasive techniques in breast cancer treatment. , 2001, Seminars in surgical oncology.

[29]  M. Corbett,et al.  A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. , 2010, Health technology assessment.

[30]  E. Moros,et al.  Present and future technology for simultaneous superficial thermoradiotherapy of breast cancer , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[31]  G. Hitchings,et al.  THE CHEMISTRY AND BIOCHEMISTRY OF PURINE ANALOGS , 1954, Annals of the New York Academy of Sciences.

[32]  M. D. Brown,et al.  Gene delivery with synthetic (non viral) carriers. , 2001, International journal of pharmaceutics.

[33]  R. Weissleder.  A clearer vision for in vivo imaging , 2001, Nature Biotechnology.

[34]  Y. Maitani,et al.  Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase , 2005, Cancer Gene Therapy.

[35]  Wei Lu,et al.  Targeted Photothermal Ablation of Murine Melanomas with Melanocyte-Stimulating Hormone Analog–Conjugated Hollow Gold Nanospheres , 2009, Clinical Cancer Research.

[36]  Robert J Griffin,et al.  Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[37]  A. Naef.  Hugh Morriston Davies: first dissection lobectomy in 1912. , 1993, The Annals of thoracic surgery.

[38]  H. Honda,et al.  Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune‐response induction in transplanted syngeneic rats , 2005, The Prostate.

[39]  Michael J Sailor,et al.  Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. , 2009, Cancer research.

[40]  C. Balagué,et al.  Replicative adenoviruses for cancer therapy , 2000, Nature Biotechnology.

[41]  Lei Xing,et al.  Image-Guided and Adaptive Radiation Therapy , 2012 .

[42]  François Guillemin,et al.  Nanoparticles as vehicles for delivery of photodynamic therapy agents. , 2008, Trends in biotechnology.

[43]  Sungho Jin,et al.  Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. , 2007, Biomaterials.

[44]  C. Heidelberger,et al.  Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.

[45]  R. Ivkov,et al.  Short communication: nanoparticle thermotherapy and external beam radiation therapy for human prostate cancer cells. , 2008, Cancer biotherapy & radiopharmaceuticals.

[46]  S. Caruthers,et al.  Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions , 2010, Angiogenesis.

[47]  Azam Bolhassani,et al.  Improvement of different vaccine delivery systems for cancer therapy , 2011, Molecular Cancer.

[48]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. , 1954, The Journal of biological chemistry.

[49]  Alexey Lugovskoy,et al.  Design of next-generation protein therapeutics. , 2010, Current opinion in chemical biology.

[50]  R. Beart,et al.  Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. , 2000, Human gene therapy.

[51]  F. Wilner,et al.  Combination chemotherapy in the treatment of advanced Hodgkin's disease. , 1975, Michigan medicine.

[52]  P. A. Scolnik,et al.  mAbs: a business perspective. , 2009, mAbs.

[53]  Aibing Yu,et al.  Inorganic nanoparticles as carriers for efficient cellular delivery , 2006 .

[54]  N. Vilaboa,et al.  Regulatable gene expression systems for gene therapy. , 2006, Current gene therapy.

[55]  R. Kopelman,et al.  The Embedding of Meta‐tetra(Hydroxyphenyl)‐Chlorin into Silica Nanoparticle Platforms for Photodynamic Therapy and Their Singlet Oxygen Production and pH‐dependent Optical Properties ¶ , 2003, Photochemistry and photobiology.

[56]  Peter Wust,et al.  Magnetic nanoparticle hyperthermia for prostate cancer , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[57]  Makoto Hashizume.  MRI-guided laparoscopic and robotic surgery for malignancies , 2007, International Journal of Clinical Oncology.

[58]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[59]  R. Hertz,et al.  Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. , 1958, The New England journal of medicine.

[60]  P. Chow,et al.  Thermoresponsive core–shell magnetic nanoparticles for combined modalities of cancer therapy , 2009, Nanotechnology.

[61]  C. P. Rhoads,et al.  Acth‐ and cortisone‐induced regression of lymphoid tumors in man. A preliminary report , 1949 .

[62]  S. Yla-Herttuala,et al.  A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro®) after intracerebral administration , 2009, The journal of gene medicine.

[63]  A. Plückthun,et al.  Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. , 1988, Science.

[64]  Jun Yoshida,et al.  Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. , 1999, Japanese journal of cancer research : Gann.

[65]  Shan Jiang,et al.  Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.

[66]  S. Groshen,et al.  Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. , 2000, Cancer research.

[67]  H. Davies.  Recent advances in the surgery of the lung and pleura , 1913 .

[68]  W. Miles.  A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon (1908). , 1908, CA: a cancer journal for clinicians.

[69]  M. Ayala,et al.  High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen. , 1999, Journal of biotechnology.

[70]  V. Devita,et al.  Preliminary clinical studies with ibenzmethyzin , 1966, Clinical pharmacology and therapeutics.

[71]  Naomi J. Halas,et al.  Nanoengineering of optical resonances , 1998 .

[72]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[73]  B. Czepulkowski,et al.  A human myeloma cell line suitable for the generation of human monoclonal antibodies. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[74]  M. Valladares,et al.  H24: a human monoclonal antibody obtained from mice carrying human Ig genes, recognises human myeloid leukaemia and CD5- Non-Hodgkin's lymphoma , 2004 .

[75]  Yong Zhang,et al.  Nanoparticles in photodynamic therapy: an emerging paradigm. , 2008, Advanced drug delivery reviews.

[76]  W. Miles.  A method of performing abdomino‐perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon (1908) , 1971 .

[77]  Hiroyuki Honda,et al.  Heat-inducible TNF-α gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy , 2001, Cancer Gene Therapy.

[78]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[79]  K. Brunner,et al.  A METHYLHYDRAZINE DERIVATIVE IN HODGKIN'S DISEASE AND OTHER MALIGNANT NEOPLASMS. THERAPEUTIC AND TOXIC EFFECTS STUDIED IN 51 PATIENTS. , 1965, Annals of internal medicine.

[80]  R. Weichselbaum,et al.  Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers , 2009, Cancer Gene Therapy.

[81]  V. Devita,et al.  ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY , 1975, The Lancet.

[82]  L. Einhorn,et al.  Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. , 1979, Seminars in oncology.

[83]  Yun Chen,et al.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  Simona Jevševar,et al.  PEGylation of therapeutic proteins , 2010, Biotechnology journal.

[85]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VII. 2, 4-Diaminopyrimidines. , 1952, The Journal of biological chemistry.

[86]  Jennifer Sturgis,et al.  A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. , 2007, Nano letters.

[87]  H. Fang,et al.  Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.

[88]  N. Vilaboa,et al.  Deliberate Regulation of Therapeutic Transgenes , 2008 .

[89]  Jennifer L. West,et al.  Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines , 2007, Journal of Neuro-Oncology.

[90]  Jun Yoshida,et al.  Intracellular Hyperthermia for Cancer Using Magnetite Cationic Liposomes: Ex vivo Study , 1996, Japanese journal of cancer research : Gann.

[91]  Robert Langer,et al.  Nanotechnology in drug delivery and tissue engineering: from discovery to applications. , 2010, Nano letters.

[92]  M. Atkins,et al.  A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma , 2010, Melanoma research.

[93]  J. West,et al.  Near-infrared-resonant gold/gold sulfide nanoparticles as a photothermal cancer therapeutic agent. , 2010, Small.

[94]  B. Hooper.  Optical-thermal response of laser-irradiated tissue , 1996 .

[95]  E. Frei,et al.  Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. , 2016, Cancer research.

[96]  Christian Bergemann,et al.  Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. , 2008, Biomaterials.

[97]  F. Sánchez‐Madrid,et al.  The use of transgenic mice for the production of a human monoclonal antibody specific for human CD69 antigen. , 2003, Journal of immunological methods.

[98]  May D. Wang,et al.  In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags , 2008, Nature Biotechnology.

[99]  Sungho Jin,et al.  Magnetic nanoparticles for theragnostics. , 2009, Advanced drug delivery reviews.

[100]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[101]  M. Foldvari,et al.  Non-viral nucleic acid delivery: key challenges and future directions. , 2011, Current drug delivery.

[102]  R. R. Robinson,et al.  Escherichia coli secretion of an active chimeric antibody fragment. , 1988, Science.

[103]  Á. González-Fernández,et al.  Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody responses in transgenic mice. , 2006, Molecular immunology.

[104]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[105]  Prashant K. Jain,et al.  Plasmonic photothermal therapy (PPTT) using gold nanoparticles , 2008, Lasers in Medical Science.

[106]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[107]  L. Einhorn.  Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. , 1981, Cancer research.

[108]  J. Roth,et al.  Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck , 2009, Clinical Cancer Research.

[109]  T. Wirth,et al.  Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. , 2008, Current molecular pharmacology.

[110]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[111]  M. Timko,et al.  Acute toxicity of magnetic nanoparticles in mice. , 2006, Neuro - endocrinology letters.

[112]  P Wust,et al.  Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial , 2007, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[113]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[114]  Y. Maitani,et al.  Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[115]  Yoon Yeo,et al.  Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. , 2009, Molecular pharmaceutics.

[116]  Donghoon Lee,et al.  Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. , 2008, Nanomedicine.

[117]  S. Kon,et al.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. , 1982, The New England journal of medicine.

[118]  L. Einhorn,et al.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.

[119]  M. J. van den Bent,et al.  Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. , 2010, Future oncology.

[120]  M. Neuberger,et al.  Production of Antigen-Specific Human Monoclonal Antibodies: Comparison of Mice Carrying IgH/κ or IgH/κ/λ Transloci , 2002 .

[121]  S. Tonegawa,et al.  Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[122]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[123]  M. Hurwitz.  Today's Thermal Therapy: Not Your Father's Hyperthermia: Challenges and Opportunities in Application of Hyperthermia for the 21st Century Cancer Patient , 2010, American journal of clinical oncology.

[124]  Peter Wust,et al.  Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.